Status:
RECRUITING
TME Alteration in HER2 Positive Breast Cancer
Lead Sponsor:
Seoul National University Hospital
Conditions:
Breast Cancer
HER2-positive Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Evaluate for changes in the tumor microenvironment before/during neoadjuvant chemotherapy and after treatment in patients diagnosed with HER2-positive advanced breast cancer and receiving neoadjuvant ...
Eligibility Criteria
Inclusion
- Inclusion criteria i. Adult patients over 18 years of age ii. Patients undergoing curative treatment including neoadjuvant chemotherapy after confirmation of breast cancer without distant metastases iii. Clinical T stage II-IV patients iv. HER2 positive breast cancer patients
- Exclusion criteria If you have other comorbidities that, according to the researcher's judgment, may affect the results of the study
Exclusion
Key Trial Info
Start Date :
July 19 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 19 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06533670
Start Date
July 19 2024
End Date
July 19 2026
Last Update
August 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea